Study results show immunotherapy before and after surgery for advanced melanoma lowers recurrence risk

<p>Contact: Eileen Teves, 210-450-7239, tevese@uthscsa.edu SAN ANTONIO – Mays Cancer Center at UT Health San Antonio melanoma expert Monte Shaheen, MD, was part of a team of investigators that conducted a phase II clinical trial funded by the National Cancer Institute (NCI) to determine the efficacy and safety of administering the immunotherapy drug pembrolizumab before [&hellip;]</p>